Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company offers cerebrum, a small molecule platform for CNS small molecule therapies and solidus, an antisense oligonucleotide platform to discover and develop antisense oligonucleotide. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020; and PRAX-050. In addition, the company develops elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080; PRAX-090; and PRAX-100. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Praxis Precision Medicines (PRAX) and Eli Lilly & Co...

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Eli Lilly & Co (LLY)

Praxis Precision Medicines ( ($PRAX) ) has provided an announcement. On May 7, 2026, Praxis Precision Medicines reported first-quarter 2026 results...

Praxis Highlights FDA NDA Acceptances and Strengthened Cash Runway

Praxis Precision Medicines, Inc. (($PRAX)) has held its Q1 earnings call. Read on for the main highlights of the call. Praxis Precision Medicines’ ...

Praxis Precision Medicines Maps High-Stakes Launch Path

In a report released today, Laura Chico from Wedbush maintained a Sell rating on Praxis Precision Medicines, with a price target of $166.00. Chico ...

Wedbush Remains a Sell on Praxis Precision Medicines (PRAX)

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Praxis Precision Medicines today and set a price target of $1,245.00. According to ...

H.C. Wainwright Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Monte Rosa Therapeutics (GLUE) and Praxis Precision ...

Market Cap	$8.94B	P/E Ratio	N/A
52W High	$358.76	52W Low	$35.21
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	42.1%	52W Position	97.5%
Overall Score	51	Value Score	45
Quality Score	47	Technical Score	63

EPS Current Est	$-14.79	EPS Next Est	$-10.95
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PRAX	$350.60	+2.05%	384.66K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PRAX	$350.60	+2.0%	384.66K
3
4
5
6

PRAX

PRAX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Praxis Precision Medicines Inc. Data in Excel

Get Praxis Precision Medicines Inc. Data in Excel